Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 26, 2022 (5 years ago)

CITALOPRAM Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Cause type: Temperature excursion

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled. All temperature excursion recalls.

What was recalled

CITALOPRAM Tablets, USP, 20MG, 100 Tablets, Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 0378-6232-01

Affected NDC 0378-6232-01

Compare with the code on your package — it is the most precise check available.

Drug: Citalopram Category: Mental Health Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Citalopram
NDC 00378-6232
HYDROBROMIDE 20 mg/1 Tablet, Film Coated
Oral
Mylan Pharmaceuticals Inc. Rx
Recalling firm
Cardinal Healthcare
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0173-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Citalopram recalls

See all
Class III · Low risk

Citalopram Oral Solution

Failed Impurities/Degradation Specifications; high out of specification results obtained at the 9 month stability timepoint

Terminated Impurity / degradation PAI Holdings, LLC. dba Pharmaceutical Associates Inc NDC 0121-1696-40 D-0015-2021
Class II · Moderate risk

Citalopram Hydrobromide active pharmaceutical ingredient packaged…

Penicillin Cross Contamination: All lots of all products repackaged between 01/05/12 through 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-591-2015
Class II · Moderate risk

CITALOPRAM Tablet

Labeling:Label Mixup; CITALOPRAM Tablet, 10 mg may be potentially mislabeled as OXYBUTYNIN CHLORIDE, Tablet, 5 mg, NDC 00603497521, Pedigree: AD52778_61, EXP: 5/20/2014; COENZYME Q-10, Capsule, 30 mg, NDC 00904501546, Pedigree: W002814, EXP: 6/7/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-630-2014
Class II · Moderate risk

Citalopram tablets USP

Chemical Contamination: The product is being recalled due to complaints reporting a strong garlic odor or strong chemical smell.

Terminated Chemical / undeclared Dr. Reddy's Laboratories, Inc. NDC 55111-344-30 D-180-2013

Other recalls by Cardinal Healthcare

All 2022 recalls
Class II · Moderate risk

Inhub Wixela

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Terminated Temperature excursion Cardinal Healthcare D-0202-2024
Class II · Moderate risk

Warfarin Sodium Tablets

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Terminated Temperature excursion Cardinal Healthcare D-0201-2024
Class II · Moderate risk

Warfarin Sodium Tablets

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Terminated Temperature excursion Cardinal Healthcare D-0200-2024